Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01061723
Registration number
NCT01061723
Ethics application status
Date submitted
2/02/2010
Date registered
3/02/2010
Date last updated
8/08/2017
Titles & IDs
Public title
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
Query!
Scientific title
A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Participants With Ankylosing Spondylitis (AS)
Query!
Secondary ID [1]
0
0
2009-016068-35
Query!
Secondary ID [2]
0
0
DRI11073
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ALIGN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ankylosing Spondylitis
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sarilumab
Treatment: Drugs - Placebo
Placebo Comparator: Placebo - Placebo (for sarilumab) weekly (qw) for 12 weeks.
Experimental: Sarilumab 100 mg q2w - Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
Experimental: Sarilumab 150 mg q2w - Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
Experimental: Sarilumab 100 mg qw - Sarilumab 100 mg SC injection qw for 12 weeks.
Experimental: Sarilumab 200 mg q2w - Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
Experimental: Sarilumab 150 mg qw - Sarilumab 150 mg SC injection qw for 12 weeks.
Treatment: Drugs: Sarilumab
Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous
Treatment: Drugs: Placebo
Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12
Query!
Assessment method [1]
0
0
Clinical response to treatment for ASAS20 was assessed according to ASAS20 criteria. Treatment response for ASAS20 was defined as an improvement by a decrease of =20% and =1unit on a 0 (no pain) - 10 (most severe pain) numerical rating scale (NRS) in at least 3 of the 4 ASAS improvement criteria (ASAS-IC) domains: assessment of physical function (measured by Bath Ankylosing Spondylitis Functional Index [BASFI]), back pain (0-10 NRS), participant global assessment (0-10 NRS) and inflammation (measured as the mean of the last 2 Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] questions) and no worsening (increase in score) of =20% and =1 unit on a 0-10 NRS in the remaining 4th domain.
Query!
Timepoint [1]
0
0
Baseline to Week 12 (Last Observation Carried Forward [LOCF])
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12
Query!
Assessment method [1]
0
0
Clinical response to treatment for ASAS40 was assessed according to ASAS40 criteria. Treatment response for ASAS40 was defined as an improvement by a decrease of =40% and =2 units on a 0 (no pain)-10 (most severe pain) NRS in at least 3 of the 4 ASAS-IC domains (participant global assessment, back pain, physical function and inflammation) and no worsening (increase in score) at all in the remaining 4th domain.
Query!
Timepoint [1]
0
0
Baseline to Week 12 (LOCF)
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12
Query!
Assessment method [2]
0
0
Participants were classified as having achieved ASAS partial remission if they had a value = 2 units on a 0 -10 NRS in each of the 4 domains: (participant global assessment, back pain, physical function and inflammation) of the ASAS-IC.
Query!
Timepoint [2]
0
0
Baseline to Week 12 (LOCF)
Query!
Secondary outcome [3]
0
0
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12
Query!
Assessment method [3]
0
0
ASDAS consists of five components: (Total back pain assessed by BASDAI question 2 on a 0 [no pain] - 10 [most severe pain] NRS, participant global of disease activity on a 0 [none] - 10 [severe] NRS, peripheral pain/swelling assessed by BASDAI question 3 on a 0 [none] - 10 [most severe pain] NRS, duration of morning stiffness assessed by BASDAI question 6 on a NRS from 0 [0 hour] - 10 [2 or more hours] and hs-CRP in mg/L). ASDAS score was calculated as follows: 0.121 x total back pain + 0.110 x participant global of disease activity + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(CRP + 1). The scores were categorized as: inactive disease (< 1.3), moderate (1.3 - < 2.1), high (2.1 - 3.5) and very high disease activity (> 3.5).
Query!
Timepoint [3]
0
0
Baseline, Week 12 (LOCF)
Query!
Secondary outcome [4]
0
0
Change From Baseline in BASDAI Score at Week 12
Query!
Assessment method [4]
0
0
BASDAI comprises of a 0 (no pain) -10 (very severe pain) NRS, used to answer 6 questions (Q) related to symptoms of AS (fatigue/tiredness, neck, back or hip pain, pain / swelling in joints, discomfort in tender areas, morning stiffness duration and morning stiffness severity). The BASDAI total score was calculated by computing the mean of Q5 and Q6 and adding it to the sum of Q1 to Q4. This score was then divided by 5. BASDAI total score=Q1+Q2+Q3+Q4+[Q5+Q6/2]/5. The total BASDAI score ranges from 0=none to 10=severe, where lower score indicated less disease activity.
Query!
Timepoint [4]
0
0
Baseline, Week 12 (LOCF)
Query!
Secondary outcome [5]
0
0
Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12
Query!
Assessment method [5]
0
0
The range of motion was measured by the BASMI (11-point scale) including chest expansion in cm. It composed of 5 clinical measurements associated with a score: tragus to wall distance, modified schober's test, lateral spinal flexion, intermalleolar distance and cervical rotation. BASMI score was calculated by dividing the total of the score by 5, and the score ranges from 0-10. Higher BASMI score indicates more severe limitation of movement.
Query!
Timepoint [5]
0
0
Baseline, Week 12 (LOCF)
Query!
Secondary outcome [6]
0
0
Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12
Query!
Assessment method [6]
0
0
ASspiMRI-a scoring system was used on all MRIs to score the level of the disease. MRIs were obtained using 1.0 or 1.5 Tesla scanners and phased array coils. Sagittal images of the upper (C2 to T10) and lower (T8 to S1) spine were used using both T1 weighted spin echo and fat saturated Short Tau Inversion Recovery (STIR) sequences. Each vertebral body unit was given an activity score based on the amount of bone marrow edema or erosion. Both T1 and STIR sequences were analyzed for change. Total spine ASspiMRI-a score in the Berlin modification range from 0 to 69 with higher scores indicating higher disease activity. A negative value in total spine ASspiMRI-a score change from baseline indicates an improvement from baseline. The higher the negative value the higher the reduction of inflammation.
Query!
Timepoint [6]
0
0
Baseline, Week 12
Query!
Secondary outcome [7]
0
0
Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12
Query!
Assessment method [7]
0
0
ASAS 5/6 responder had an improvement of 20% in 5 of 6 domains (physical function, back pain, participant global assessment, inflammation, spinal mobility and acute phase reactants) of ASAS-IC without deterioration in the 6th domain. Spinal mobility was assessed by the mean of the 5 BASMI scores on the 11-point scale (score ranges from 0-10) and the hs-CRP for the acute phase reactant.
Query!
Timepoint [7]
0
0
Baseline to Week 12 (LOCF)
Query!
Secondary outcome [8]
0
0
Change From Baseline in Chest Expansion at Week 12
Query!
Assessment method [8]
0
0
The difference between maximal inspiration and expiration to the nearest 0.1 cm was recorded. The best of 2 tries were recorded.
Query!
Timepoint [8]
0
0
Baseline, Week 12 (LOCF)
Query!
Secondary outcome [9]
0
0
Change From Baseline in Swollen Joint Index at Week 12
Query!
Assessment method [9]
0
0
44 swollen joints were examined including sternal, clavicular, elbow, shoulder, wrist, knee, metacarpophalangian, interphalangian, metatarpophalangian and metatarsophalangeal joints.
Query!
Timepoint [9]
0
0
Baseline, Week 12 (LOCF)
Query!
Secondary outcome [10]
0
0
Change From Baseline in Hs-CRP at Week 12
Query!
Assessment method [10]
0
0
Participant's blood samples were collected at screening, baseline before dosing and at every visit to evaluate the level of hs-CRP. The hs-CRP is a protein marker in the blood associated with inflammation with higher values indicating a greater degree of inflammation.
Query!
Timepoint [10]
0
0
Baseline, Week 12 (LOCF)
Query!
Secondary outcome [11]
0
0
Change From Baseline in ASAS Individual Components at Week 12
Query!
Assessment method [11]
0
0
ASAS consists of 4 individual components: Participant global assessment to assess the disease activity over the last week on a 0 (no pain) - 10 (severe pain) NRS; back pain which consist of the mean of the nocturnal back pain and the total back pain at every visit on a 0 (no pain) - 10 (most severe pain) NRS; inflammation measured as the mean of the last 2 BASDAI questions (intensity and duration of morning stiffness) and physical function measured as mean of 10 scores of BASFI at every visit on 0 (easy) -10 (impossible) NRS. Lower score corresponds to a better functioning.
Query!
Timepoint [11]
0
0
Baseline, Week 12 (LOCF)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Diagnosis of AS according to the New York modified criteria
- Participants must had an adequate trial of at least 2 different Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) taken for at least 2 weeks in each case and, on a
stable dose for =2 weeks or be intolerant to NSAIDs
- Participants must had active AS for =3 months before screening and active disease must
be present at screening and at baseline; Active AS being defined by:
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of =4
(Numerical Rating Scale 0-10)
- Total back pain score =4 (Numerical Rating Scale 0-10)
Participants treated with corticosteroid must be on a stable dose for =2 weeks prior to
baseline
Participants treated with the Disease Modifying Anti-Rheumatic Drugs (DMARDs)
hydroxychloroquine, sulfasalazine and methotrexate (MTX) must be on stable dose =12 weeks
prior to baseline
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- <18 years old or =75 years old
- Complete fusion of the spine
- Past history of non response to any anti-Tumor Necrosis Factors (TNFs) treatment or
non response to any other biological treatment for AS
- Any past or current treatment with anti-TNF's or any biological agent within 3 months
prior to screening
- Treatment with DMARDs except for hydroxychloroquine, sulfasalazine and MTX
- MTX >25 mg/week
- hydroxychloroquine >400 mg/day
- Sulfasalazine >3 g/day
- Treatment with oral prednisone or equivalent corticosteroids >10 mg/day within 6 weeks
prior to screening
- Use of intramuscular or intra-articular corticosteroids within the last 4 weeks before
screening
- Previous treatment with cyclosporine, azathioprine
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
301
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 036001 - East Malvern
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 036003 - Hobart
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 036004 - Shenton Park
Query!
Recruitment hospital [4]
0
0
Investigational Site Number 036002 - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
3145 - East Malvern
Query!
Recruitment postcode(s) [2]
0
0
7001 - Hobart
Query!
Recruitment postcode(s) [3]
0
0
6008 - Shenton Park
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Idaho
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maryland
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Graz
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Wien
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Brussels
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Genk
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Gent
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Liège
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
London
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Montreal
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Newmarket
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Pointe-Claire
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Quebec
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Saskatoon
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
Toronto
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Trois-Rivières
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Vancouver
Query!
Country [34]
0
0
Czechia
Query!
State/province [34]
0
0
Brno
Query!
Country [35]
0
0
Czechia
Query!
State/province [35]
0
0
Hlucin
Query!
Country [36]
0
0
Czechia
Query!
State/province [36]
0
0
Hradec Kralove
Query!
Country [37]
0
0
Czechia
Query!
State/province [37]
0
0
Praha 2
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Uherske Hradiste
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Besancon
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bordeaux
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Creteil Cedex
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Paris
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Erlangen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Frankfurt Am Main
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Hamburg
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Herne
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Budapest
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Debrecen
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Sátoraljaújhely
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Veszprém
Query!
Country [52]
0
0
Lithuania
Query!
State/province [52]
0
0
Kaunas
Query!
Country [53]
0
0
Lithuania
Query!
State/province [53]
0
0
Vilnius
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Amsterdam
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Nijmegen
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Bialystok
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Krakow
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Lublin
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Torun
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Warszawa
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Barcelona
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
La Coruña
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Madrid
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Sevilla
Query!
Country [65]
0
0
Turkey
Query!
State/province [65]
0
0
Ankara
Query!
Country [66]
0
0
Turkey
Query!
State/province [66]
0
0
Izmir
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Regeneron Pharmaceuticals
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary objective:
- to evaluate the efficacy of Sarilumab in participants with Ankylosing Spondylitis (AS)
using the assessment in AS working group criteria (ASAS) 20% response criteria (ASAS20)
Secondary objectives:
- to demonstrate that Sarilumab was effective on:
- assessment of higher level of response [ASAS 40% response criteria (ASAS40)]
- partial remission
- disease activity
- range of motion
- Magnetic Resonance Imaging (MRI) of the spine
- to assess the safety and tolerability of Sarilumab in participants with AS as well as
the pharmacokinetic profile of Sarilumab in participants with AS
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01061723
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01061723
Download to PDF